H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report) on May 20 and set a price target of $26.00. The company's shares closed last Friday at $2.01, close to its 52-week low of $1.80. According to TipRanks.com, Caufield has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -19.3% and a 26.7% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Gemini Therapeutics, and IVERIC bio. Ocuphire Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-ocuphire-pharmas-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral